GITNUX MARKETDATA
Browse Our Category
Medical Conditions Disorders
Latest update:
Allergy Statistics
Asthma and allergic rhinitis are not niche problems. In 2025, asthma is linked to 4.3% of global deaths while the U.S. still reports hay fever in about 10% of people and adult asthma affects 8.6%, with millions of children and rising allergy spending and therapies reshaping how clinicians diagnose and manage these conditions.
Tourette Syndrome Statistics
Sleep problems affect about 52% of people with Tourette syndrome yet several treatments show measurable relief, from botulinum toxin that can reduce focal motor tics for roughly 3 to 4 months to CBIT that lowers tic related impairment on the YGTSS. The page also tracks what often follows tics into adulthood, with 35% reporting persistent symptoms, comorbid ADHD and OCD at striking rates, and real world cost and access signals that help explain why consistent care can be so hard to get.
Fibromyalgia Statistics
Fibromyalgia affects about 0.5% of U.S. adults overall but rises sharply with age and sex, with estimates reaching 7.4% among women and 3.6% among men, and about 7.2% in adults 65 and older, plus nearly half the story is daily reality since people report moderate to severe pain on 72% of days. This page connects prevalence with day to day symptoms, work loss, disability odds, and treatment patterns so you can see how a condition often described as “invisible” shows up in sleep, healthcare use, and costs.
Global Diabetes Statistics
Diabetes is already costing the world USD 966 billion in health spending in 2021 and driving losses beyond the clinic, with USD 413 billion in annual premature mortality and disability impacts. One page tracks how 537 million adults lived with diabetes in 2021, how 46% were undiagnosed, and why treatment and productivity totals keep accelerating toward an estimated USD 1 trillion by 2045.
Osteosarcoma Statistics
See how osteosarcoma survival can hinge on details like pathology necrosis thresholds and complete metastasectomy, with SEER covering about 48% of the US population and standard MAP chemotherapy producing 70% 5 year overall survival on the EURAMOS 1 backbone. You will also find clinic ready markers such as ALP and LDH, plus why MRI staging and FDG PET CT can change how quickly disease is recognized and treated.
Anal Cancer Statistics
Anal canal cancers account for 2.8% of colorectal cancers, yet they are disproportionately driven by oncogenic HPV and higher risk groups, where persistent HPV16 or 18 raises progression risk with a hazard ratio of 5.0 and HIV increases risk up to a 33 fold relative jump. On this 2026 updated statistics page, you can connect what drives incidence and survival, from HPV vaccination and screening thresholds to definitive chemoradiation complete response near 69% and global mortality of 1.5 per 100,000, and see why the pathway to treatment matters as much as the tumor.
Cancer Survival Rates Statistics
Cancer Survival Rates charts how outcomes vary by stage, biology, and where you live, using the most recent US figures such as a 5 year overall cancer relative survival of 68.7% from 2014 to 2020 and breast cancer localized survival at 99.3% compared with just 31.9% for distant metastatic disease. You will also see the gaps targeted therapy and treatment strategy can close, including HER2 and early stage boosts over 90% and how survival differs across groups, like 81.6% for Black women versus 91.4% for white women in 2014 to 2020.
Uterus Cancer Statistics
See why uterine cancer risk can change dramatically across biology and behavior, from Black women facing 2.5 times the age adjusted incidence of White women in US SEER data (2015–2019) to obesity and diabetes raising endometrial cancer risk while combined oral contraceptives, physical activity, and even smoking are linked to lower risk. You will also find treatment trial outcomes that are reshaping care, since immunotherapy options for dMMR or MSI-H endometrial cancer have moved from promising signals to measurable improvements in progression free survival.
Measles Outbreak Statistics
Measles still spreads with a herd immunity threshold of about 95% and can infect susceptible contacts at a secondary attack rate of 0.3, so small coverage gaps of just 5 to 10 percentage points can be enough to restart outbreaks. Learn how WHO estimates 66 million children were unvaccinated and why complications linked to measles can drive long term economic and social harm alongside a 97% vaccine effectiveness after one dose.
Chronic Kidney Disease Statistics
Nearly 37.0% of US adults with chronic kidney disease do not know they have it, even as prevalence rose from 13.1% in 1999–2004 to 14.3% by 2015–2018. See how early detection gaps translate into hard outcomes and costs worldwide and in the US, plus why treatments that target kidney and heart risk can cut progression and death meaningfully.
Lactose Intolerance Statistics
A staggering 1.7 billion people worldwide are estimated to have lactose maldigestion, and the pattern is shifting from symptoms to measurable biology with H2 breath tests often turning positive within about 90 minutes. You will see how lactose free and lactose reduced dairy are gaining ground with 7.5% CAGR forecast for lactose free dairy from 2023 to 2030 while study results show that a 10 g lactose dose can trigger symptoms in a third of malabsorbers but only 7% of tolerant controls.
Alzheimers Statistics
See why dementia weighs far beyond memory with Alzheimer’s driving 60–70% of dementia cases and costing an average $37,000 per person each year in the US. This page puts cutting edge 2025 and newer themes into focus, from faster, biomarker supported diagnoses to the care and trial pipeline behind anti amyloid progress, alongside the practical gaps that still hit families earliest.
Copd Hospitalization Statistics
Every year, COPD hospitalizations stack up with real consequences, from 464,000 Medicare discharges for COPD as the principal diagnosis and about 6.7% 30 day mortality to readmission rates that can reach 20% after discharge. Learn how exacerbations drive 60% of COPD’s economic burden and why treatment choices like inhaler adherence, vaccination, and pulmonary rehabilitation are linked to meaningfully lower hospitalization and readmission risk.
Anaphylaxis Statistics
Anaphylaxis can look like a sudden, unpreventable crisis, yet only about 0.3% to 1% of reported cases end in death while many episodes still happen during hospitalization, making timing and care decisions feel more consequential than the mortality rate itself. This page also tracks who is most at risk and why, from a 14.3% survey estimate of any prior anaphylaxis history in US adults to the recurring gaps in epinephrine access, training, and correct device use.
Dengue Fever Statistics
In 2019, dengue was estimated to infect about 241 million people worldwide, yet modeled total infections average closer to 390 million per year, including mild and asymptomatic cases, so the burden is far larger than routine counts suggest. The page links global burden measures to regional pressure points like the Western Pacific’s 70 percent share of cases and maps how temperature, rainfall, and seasonal post rain surges help explain why outbreaks accelerate, with vaccine trial benchmarks and transmission timing that make risk feel less abstract.
Trichomoniasis Statistics
In the United States, trichomoniasis affects about 3.7 million people and is highest among women aged 35 to 49 at 3.2 percent, yet symptoms show up for fewer than 30 percent. This page connects risk factors to real odds, from commercial sex work raising risk tenfold to NAAT tests delivering 95.1 percent sensitivity for women, so you can see why accurate screening and treatment matter.
Huntington Disease Statistics
Chorea hits 90% of people with Huntington disease, but the real timeline pressure comes earlier with cognitive decline in 50% by diagnosis and dementia nearing all patients, so this page turns symptoms into something you can plan around. You will also see the 44 to 45 CAG repeat reality behind onset at 44 years, the 15 to 20 year path from onset to death, and how modern genetic and imaging markers now sharpen risk long before manifest disease.
Vitiligo Statistics
Vitiligo affects about 0.5% of the world’s population, yet its burden stretches well beyond skin with depressive symptoms reported by 54% of patients and psychiatric comorbidity showing higher odds in pooled analyses. You will also see how fast treatment can start, with a U.S. claims study finding first line therapy begins about 45 days after diagnosis, alongside surprising comorbidity patterns like autoimmune thyroid disease in 20% and rheumatoid arthritis in 4%.
Osteoarthritis Statistics
Osteoarthritis contributes just 0.6% of global disability burden yet up to 80% of people with the condition report pain, making treatment impact feel far larger than the overall share. See how evidence-based options shift outcomes, from exercise and 5% to 10% weight loss to injections that ease symptoms for only weeks and surgery that delivers WOMAC pain and function gains, alongside the cost and guideline facts that shape real-world care.
Gum Disease Statistics
Severe periodontitis affects 8.7% of U.S. adults aged 30 and older, yet a striking 83% of people with periodontitis have no symptoms, making prevention and routine care feel like the only early warning system. This page also contrasts global burden and modifiable risk with estimates like about 30% of adults aged 35 and older living with periodontitis and shows what evidence-based treatments and maintenance can realistically change.